MLYS Mineralys: Earnings per share for the trailing year

Mineralys Therapeutics (MLYS) is developing a hypertension drug for lifelong use, ensuring a steady stream of cash. On GURU.Markets, the annual EPS growth rate over the last 12 months illustrates the market response, where the -47.20 mark serves as a key metric. The brand has earned trust through innovations in cardiology, while its environmental strategy is currently at the stage of basic compliance with laboratory standards.
MLYS (mineralystx.com): analytical breakdowns and indicator data

Investors utilize this metric to evaluate net earnings per share dynamics, determining the business's ability to scale profitability amid volatility. The indicator measures the annual growth of rolling earnings over four quarters, which, for the asset-light model of Mineralys Therapeutics (MLYS) utilizing contract manufacturing organizations (CMO), reflects the efficiency of R&D cost management, as clearly demonstrated by the historical EPS YoY TTM delta.